Safety of intravenous ciprofloxacin

Article Abstract:

The safety of the quinolone antibiotic ciprofloxacin given intravenously, or directly into the circulation, was examined in 1,869 patients with an average age of 50 years. Most of the patients had at least one systemic illness, or illness affecting the entire body, and were in fair or poor health at the beginning of treatment. Adverse effects occurred in 15.8 percent of 1,878 courses of therapy, and ciprofloxacin was discontinued early in three percent. Local reactions at the site of injection were the most common adverse side effect and occurred in 4.4 percent of the courses. Changes in blood chemistry occurred in 4.1 percent of courses and included increases in certain enzymes, such as alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase. Three percent of the adverse effects involved the gastrointestinal tract and included nausea and diarrhea. Central nervous system effects such as convulsive seizures, headache and dizziness comprised 1.8 percent of adverse effects. In similar studies, 17.3 percent of drug-related effects were due to ciprofloxacin and 13.6 percent were due to another antibiotic, ceftazidime. The incidence of adverse effects other than local reactions at the site of injections were similar for both ciprofloxacin and ceftazidime. (Consumer Summary produced by Reliance Medical Information, Inc.)

Intravenous therapy

---

Safety of oral ciprofloxacin: an update based on clinical trial results

Article Abstract:

The safety of the fluoroquinolone antibiotic ciprofloxacin given orally in 9,473 courses of treatment worldwide was examined. The daily doses were between 200 and 2,000 milligrams orally, and 9,466 patients were involved in the study. In 4.9 percent of the treatment courses, oral ciprofloxacin was associated with adverse side effects in the digestive system, 4.4 percent in metabolism and nutrition, 1.5 percent in the central nervous system, 1.1 percent in the skin, 0.9 percent in the blood and lymphatic system, 0.8 percent in the urogenital system, 0.5 percent in the body as a whole, 0.2 percent in the cardiovascular system, 0.2 percent in the special senses, and 0.1 percent in the musculoskeletal and respiratory systems. Several patients experienced more than one side effect and the total incidence of side effects was 9.3 percent. Most of the side effects were considered mild or moderate; severe side effects occurred in 55 patients or 0.6 percent of 9,473 courses of therapy. Ciprofloxacin was discontinued in 146 patients primarily due to gastrointestinal side effects. The results demonstrate that the antibiotic ciprofloxacin given orally is safe, and side effects are mild or moderate and reversible. (Consumer Summary produced by Reliance Medical Information, Inc.)

Oral medication, Oral drugs

---

Ciprofloxacin: toxicologic evaluation of additional safety data

Article Abstract:

The long-term toxic effects of the fluoroquinolone antibiotic ciprofloxacin on joints, survival and development of the embryo, and central nervous system, including the brain and spinal cord, were examined in laboratory rats, mice, dogs, and monkeys. Amounts of ciprofloxacin of up to 5,000 parts per million (ppm) were given in the food for 24 months to rats and 21 months to mice. Ciprofloxacin did not cause any toxic effects on organ systems and did not produce tumors in rats and mice. In juvenile dogs, ciprofloxacin caused a minor widening of the recessus suprapatellaris, a structure above the joint. This effect on the joint may be used to monitor antibiotic treatment in juveniles receiving ciprofloxacin. The drug did not have lethal or teratogenic effects on the embryos of monkeys. The combination of ciprofloxacin and nonsteroidal anti-inflammatory agents caused toxic effects on the central nervous system at doses which were above the therapeutic range. (Consumer Summary produced by Reliance Medical Information, Inc.)

Joints, Joints (Anatomy), Drug therapy, Central nervous system diseases, Embryology, Experimental, Embryological research, Inflammation, Drug interactions

Similar abstracts:

• Abstracts: Resistance to ciprofloxacin appearing during therapy. Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.